Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time --
PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC ('DOMA') has nominated three candidates to stand for election to the Pacira Board of Directors (the 'Board') at the Company's 2025 Annual Meeting of Stockholders.
Pacira issued the following statement in response to DOMA's director nominations:
'Pacira's Board and management team are taking decisive action to enhance shareholder value. We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver shareholder value. The Nominating, Governance and Sustainability Committee of the Pacira Board will evaluate and consider DOMA's proposed candidates, as it does with all director candidates.'
The Board will present its formal recommendation regarding director nominees in the Company's definitive proxy statement and other materials, to be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the 2025 Annual Meeting of Stockholders.
The date of the Annual Meeting has not yet been announced and shareholders are not required to take any action at this time.
Evercore is serving as financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to the Company.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Forward-Looking Statements
Any statements in this document about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words 'believes,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'intends,' 'may,' 'will,' 'would,' 'could,' 'can' and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2025 Annual Meeting, '5x30', Pacira's growth and business strategy; Pacira's future outlook, Pacira's intellectual property and patent terms, Pacira's growth and future operating results and trends, Pacira's strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including Pacira's plans with respect to the repayment of Pacira's indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. Pacira cannot assure you that its estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; Pacira's manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and Pacira's business, including Pacira's revenues, financial condition, cash flow and results of operations; the success of Pacira's sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and Pacira's ability to serve those markets; Pacira's plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; Pacira's plans to evaluate, develop and pursue additional product candidates utilizing Pacira's proprietary multivesicular liposome ('pMVL') drug delivery technology; the approval of the commercialization of Pacira's products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; Pacira's commercialization and marketing capabilities; Pacira's ability to successfully complete capital projects; the outcome of any litigation; the recoverability of Pacira's deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of Pacira's share repurchase program; and factors discussed in the 'Risk Factors' of Pacira's most recent Annual Report on Form 10-K and in other filings that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent Pacira's views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira's views as of any date subsequent to the date of this document.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira's actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the 'Risk Factors' of Pacira's most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC.
Important Additional Information Regarding Proxy Solicitation
Pacira intends to file a proxy statement and BLUE proxy card with the U.S. Securities and Exchange Commission (the 'SEC') in connection with its solicitation of proxies for Pacira's 2025 annual meeting of stockholders (the '2025 Proxy Statement,' and such meeting the '2025 Annual Meeting'). BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING PACIRA'S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC's website at http://www.sec.gov and on Pacira's investor relations website at https://investor.pacira.com.
Participants in the Solicitation
Pacira, its directors, director nominees, certain of its executive officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2025 Annual Meeting. Information regarding the names of Pacira's directors and executive officers and their respective interests in Pacira by security holdings or otherwise is set forth in Pacira's proxy statement for the 2024 Annual Meeting of stockholders, filed with the SEC on April 22, 2024 (the '2024 Proxy Statement'). Please refer to the sections captioned 'Director Compensation,' 'Executive Compensation,' and 'Stock Ownership Information' in the 2024 Proxy Statement. To the extent holdings of such participants in Pacira's securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC: Form 4, filed by Jonathan Slonin on June 5, 2024; Form 4, filed by Daryl Gaugler on June 5, 2024; Form 4, filed by Kristen Williams on June 5, 2024; Form 4, filed by Lauren Riker on June 5, 2024; Form 4, filed by Mark A. Kronenfeld on June 13, 2024; Form 4, filed by Laura Brege on June 13, 2024; Form 4, filed by Kristen Williams on June 13, 2024; Form 4, filed by Alethia Young on June 13, 2024; Form 4, filed by Mark Froimson on June 13, 2024; Form 4, filed by Daryl Gaugler on June 13, 2024; Form 4, filed by Abraham Ceesay on June 13, 2024; Form 4, filed by Michael J. Yang on June 13, 2024; Form 4, filed by Marcelo Bigal on June 13, 2024; Form 4, filed by Christopher Christie on June 13, 2024; Form 4, filed by Jonathan Slonin on June 13, 2024; Form 4, filed by Lauren Riker on June 13, 2024; Form 4, filed by Jonathan Slonin on July 3, 2024; Form 4, filed by Daryl Gaugler on July 3, 2024; Form 4, filed by Jonathan Slonin on August 2, 2024; Form 4, filed by Marcelo Bigal on August 12, 2024; Form 4, filed by Mark Froimson on August 12, 2024; Form 4/A, filed by Marcelo Bigal on August 13, 2024; Form 4, filed by Frank D. Lee on August 13, 2024; Form 4, filed by Michael J. Yang on August 14, 2024; Form 4, filed by Laura Brege on August 19, 2024; Form 4, filed by Marcelo Bigal on August 19, 2024; Form 4, filed by Daryl Gaugler on September 13, 2024; Form 3, filed by Shawn Cross on October 23, 2024; Form 4, filed by Shawn Cross on November 5, 2024; Form 4, filed by Daryl Gaugler on December 16, 2024; Form 4, filed by Lauren Riker on January 6, 2025; Form 4, filed by Daryl Gaugler on January 6, 2025; Form 4, filed by Jonathan Slonin on January 6, 2025; Form 4, filed by Frank D. Lee on January 6, 2025; Form 3, filed by Brendan Teehan on January 28, 2025; Form 4, filed by Lauren Riker on February 4, 2025; Form 4, filed by Brendan Teehan on February 4, 2025; Form 4, filed by Frank D. Lee on February 4, 2025; Form 4, filed by Kristen Williams on February 4, 2025; and Form 4, filed by Jonathan Slonin on February 4, 2025. Additional information can also be found in Pacira's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025. Details concerning potential participants in the solicitation, including Pacira's director nominees for election at the 2025 Annual Meeting, will also be included in the 2025 Proxy Statement. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC's website at http://www.sec.gov and on Pacira's investor relations website at https://investor.pacira.com.
CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Why Tesla Stock Soared This Week
Tesla CEO Elon Musk apologized for some of his comments last week that have weakened his relationship with the White House, boosting the stock. However, the reported launch of Tesla robotaxis in Austin, Texas, has been delayed to later this month. The company's declining sales are a major concern. These 10 stocks could mint the next wave of millionaires › Shares of Tesla (NASDAQ: TSLA) are up this week, climbing 10.3% as of market close on Friday. The rise came as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both sank modestly. Tesla stock recovered this week after the public spat between CEO Elon Musk and President Trump cooled. Last week, Musk and Trump found themselves in a very public spat. What began as criticism of Trump's flagship "Big, Beautiful Bill" escalated into personal attacks and serious accusations. Musk deleted his most incendiary post and apologized on X, saying that some of his posts last week had gone "too far." The de-escalation of the situation sent Tesla stock higher. The stock was also on the rise this week in anticipation of Tesla's reported robotaxi launch. According to a report from Bloomberg, Tesla was set to begin operating its vehicles autonomously in Austin, Texas, on June 12. However, it's now clear that the company has pushed back this date, now targeting June 22. Despite the delay, Tesla shares were up further on Friday. This is not the first time the company has failed to meet a target launch date or milestone for its autonomous driving technology. Musk previously said he was "very confident predicting" that there would be 1 million of his robotaxis on the roads no later than "next year" -- in 2019. I am dubious of the company's ability to deliver on its promises, and given the state of its current vehicle sales (which are seeing massive declines), I think this stock is extremely overvalued. Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $376,048!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,816!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $655,255!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Why Tesla Stock Soared This Week was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
MGP Ingredients (NASDAQ:MGPI) investors are sitting on a loss of 68% if they invested three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term MGP Ingredients, Inc. (NASDAQ:MGPI) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 69% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 61% in the last year. More recently, the share price has dropped a further 10% in a month. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). MGP Ingredients saw its EPS decline at a compound rate of 54% per year, over the last three years. This fall in the EPS is worse than the 32% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. This positive sentiment is also reflected in the generous P/E ratio of 57.06. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on MGP Ingredients' earnings, revenue and cash flow. MGP Ingredients shareholders are down 60% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for MGP Ingredients you should be aware of. MGP Ingredients is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
3 hours ago
- Yahoo
Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller
Beaverton, Oregon-based semiconductor startup AheadComputing, founded by four former Intel (NASDAQ:INTC) central processing unit architects, announced in February that it secured $21.5 million in seed funding to develop a new class of high-performance processors based on the RISC-V architecture. The seed funding round was led by Eclipse Ventures, with participation from Maverick Capital, Fundomo, and EPIQ Capital. The company also added Jim Keller to its board of directors. Keller is widely regarded as one of the foremost chip designers in the world, having held engineering leadership roles at Apple (NASDAQ:AAPL), Advanced Micro Devices (NASDAQ:AMD), Intel, and Tesla (NASDAQ:TSLA), The Oregonian reports. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can The company, established in 2024, is aiming to design a scalable and power-efficient CPU that challenges x86 dominance in the data center and artificial intelligence sectors, The Oregonian says. Led by CEO Debbie Marr, AheadComputing intends to deliver what it calls the 'biggest, baddest CPU in the world.' RISC-V, a royalty-free, open instruction set architecture, is emerging as a credible alternative to proprietary platforms such as Intel's x86 and ARM's licensed designs. According to The Oregonian, the architecture enables companies to create customized processors without licensing restrictions or vendor lock-in. AheadComputing's team has grown to 80 employees, many of whom previously held senior roles at Intel. The company is targeting high-performance workloads in cloud infrastructure, AI inference, and edge computing applications. Its design leverages the modular 'chiplet' model, allowing for flexible system-on-chip configurations tailored to specific customer needs, The Oregonian reports. Trending: Invest where it hurts — and help millions heal:. Co-founder Jonathan Pearce told The Oregonian that the fragmentation of computing systems presents an opportunity for specialized vendors to offer optimized components within larger heterogeneous systems. 'You get the opportunity for a company like AheadComputing to provide that piece of the overall system. As opposed to the past 20 years where it was just one tech giant,' Pearce said. AheadComputing operates as a fabless semiconductor company, outsourcing chip fabrication to partners such as Taiwan Semiconductor Manufacturing Co. This capital-efficient model allows the firm to focus resources on architectural innovation and design execution, The Oregonian reports. Intel's long-standing position as Oregon's largest private employer is undergoing transition, with multiple senior engineers departing to build independent ventures. According to The Oregonian, AheadComputing represents one of the most ambitious spinouts, combining advanced design experience with startup agility. Vice president of AheadComputing's design verification Alon Mahl said the hands-on startup environment allows engineering leaders to accelerate timelines and make immediate decisions without layers of corporate oversight. The Oregonian says that the team is already seeking larger office space in Washington County to accommodate growth and additional equipment to The Oregonian, AheadComputing joins a small group of Oregon-based chip startups led by Intel alumni, including Ampere Computing, which was recently acquired by SoftBank for $6.5 billion while retaining its Portland office footprint. Portland State University professor Christof Teuscher, an expert in microprocessor architecture, said the startup is taking a high-risk, high-reward approach. While RISC-V has traditionally been used in academic and embedded contexts, The Oregonian says that Teuscher expressed skepticism about its ability to succeed in high-performance commercial environments. According to The Oregonian, AheadComputing envisions its chips will eventually power PCs, laptops, and data centers, with possible clients including Google, Amazon (NASDAQ:AMZN), and Samsung. Read Next: Here's what Americans think you need to be considered wealthy. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
